세계의 임상시험 시장 : 상별, 서비스 유형별, 치료 영역별, 용도별, 시험 디자인 전망별, 스폰서 유형별, 지역별, 기회, 예측(2017-2031년)

Clinical Trials Market Assessment, By Phase, By Service Type, By Therapeutic Area, By Application, By Study Designs Outlook, By Sponsor Type, By Region, Opportunities and Forecast, 2017-2031F

US $ 4,800 ￦ 6,983,000

PDF & Excel Printable (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF & Excel 이용 범위와 동일합니다. 인용 시에는 사전에 출판사의 허락을 받아야 합니다.

US $ 6,000 ￦ 8,729,000

PDF & Excel Printable (Corporate License)

PDF & Excel 보고서를 동일 기업 1개국 거점의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF & Excel 이용 범위와 동일합니다. 인용 시에는 사전에 출판사의 허락을 받아야 합니다.

US $ 8,500 ￦ 12,366,000

PDF & Excel Printable (Custom Research License)

PDF & Excel 보고서를 동일 기업 1개국 거점의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF & Excel 이용 범위와 동일합니다. 100시간의 애널리스트와의 시간이 포함되어 있으며, 보고서 커스터마이징 등에 사용할 수 있습니다. 인용 시에는 사전에 출판사의 허락을 받아야 합니다.

한글목차

세계의 임상시험 시장 규모는 예측 기간 동안 7.17%의 복합 연간 성장률(CAGR)로 확대될 전망이며, 2023년 623억 8,000만 달러에서 2031년에는 1,085억 5,000만 달러로 성장할 것으로 예측됩니다. 임상시험 시장의 성장은 제약회사에 의한 R&D 투자 증가와 희소질환,희소질환 치료에 대한 주목의 고조에 의해 견인될 것으로 예상됩니다. 이러한 요소는 혁신적인 연구와 새로운 치료에 대한 강한 요구를 만들어 시장 성장을 더욱 촉진합니다.

세계의 임상시험 시장은 제약기업에 의한 R&D 투자 증가에 의해 큰 성장을 이루고 있습니다. 니파바이러스 감염이나 라사열과 같은 만성 및 신질환 모두의 유행이 확대되고 있는 것이 혁신적인 치료에 대한 수요를 끌어올리고 있습니다. 신흥 시장은 비용효과와 다양한 환자층에 의해 매우 중요한 시장이 되고 있습니다. 게다가 개발을 장려하는 규제상의 우대조치에 힘입어 희소질환이나 희소질환용 의약품이 중시되도록 되어 있습니다. 원격 의료 및 웨어러블 장치를 포함한 디지털 건강 기술의 출현은 임상시험의 효율성을 향상시키고 환자 참여도를 높입니다. 예를 들어 AstraZeneca PLC는 2023년 11월 Evinova라는 새로운 이니셔티브를 도입하고 효율성을 높이고 비용을 절감하는 디지털 솔루션을 통해 임상시험을 강화하는 것을 목표로 하고 있습니다. 이러한 개발은 지속적인 기술 진보와 진화하는 규제 조건에 의해 지원됩니다.

세계의 임상시험 시장은 의약품, 의료기기, 생명공학, 의료 IT의 R&D 투자 증가로 빠르게 성장하고 있습니다. ICON plc, Biogen Inc., Novartis AG, F. Hoffmann-La Roche AG 등의 기업이 최전선에 서서 혁신을 추진하고 임상 연구 능력을 확대하고 있습니다. 그들의 공헌은 이 분야의 역동적인 진화와 확대를 두드러지게 합니다. 또한 원격 의료 및 웨어러블 장치와 같은 의료 기술의 도입은 임상시험 과정을 가속화하고 환자의 참여를 향상시킵니다. 예를 들어 Accenture PLC가 클라우드에서 임상시험 시뮬레이션에 AI를 활용하는 QuantHealth Ltd.에 전략적 투자를 실시한 것은 R&D 자금이 치료법 개발을 가속화하고 프로세스를 보다 신속하고 비용대비 효과가 높은 것인지를 나타냅니다. 이러한 노력은 R&D 투자 증가가 임상시험 시장의 진전에 큰 영향을 미칩니다는 것을 돋보이게 합니다.

본 보고서에서는 세계의 임상시험 시장에 대해 조사했으며, 시장 개요와 함께 상별, 서비스 유형별, 치료 영역별, 용도별, 시험 디자인 전망별, 스폰서 유형별, 지역별 동향 및 시장에 진입한다 기업 프로파일 등의 정보를 제공합니다.

목차

제1장 프로젝트의 범위와 정의

제2장 조사 방법

제3장 주요 요약

제4장 세계의 임상시험 시장 전망(2017년-2031년)

• 시장 규모의 분석과 예측
• 시장 점유율 분석과 예측
• 시장 맵 분석(2023년)
  • 상별
  • 서비스 유형별
  • 치료영역별
  • 용도별
  • 시험 디자인 전망별
  • 스폰서 유형별
  • 지역별

제5장 북미의 임상시험 시장 전망(2017년-2031년)

제6장 유럽의 임상시험 시장 전망(2017년-2031년)

제7장 아시아태평양의 임상시험 시장 전망(2017년-2031년)

제8장 남미의 임상시험 시장 전망(2017년-2031년)

제9장 중동 및 아프리카의 임상시험 시장 전망(2017년-2031년)

제10장 Porter's Five Forces 분석

제11장 시장 역학

제12장 시장 동향과 발전

제13장 규제 프레임워크와 혁신

제14장 사례 연구

제15장 경쟁 구도

• 시장 리더 톱 5의 경쟁 매트릭스
• 참가 기업 톱 5의 SWOT 분석
• 시장의 주요 참가 기업 톱 10의 정세
  • Thermo Fisher Scientific Inc.
  • Novo Nordisk A/S
  • IQVIA, Inc.
  • Laboratory Corporation of America Holdings
  • Caidya
  • ICON plc
  • Medpace Holdings, Inc.
  • Parexel International Corporation
  • Charles River Laboratories International, Inc.
  • SGS Societe Generale de Surveillance SA

제16장 전략적 제안

제17장 문의 및 면책사항

BJH

영문 목차

영문목차

Global clinical trials market is projected to witness a CAGR of 7.17% during the forecast period 2024-2031, growing from USD 62.38 billion in 2023 to USD 108.55 billion in 2031. The growth of the clinical trials market is expected to be driven by higher R&D investments from pharmaceutical companies coupled with rising focus on rare and orphan disease treatment. These elements will create a strong need for innovative research and new treatments, further driving the market growth.

The global clinical trials market is experiencing substantial growth, fueled by increased investments in research and development from pharmaceutical companies. The growing prevalence of both chronic and new diseases like Nipah virus infection and Lassa fever is boosting the demand for innovative treatments. Emerging markets are becoming crucial due to their cost-effectiveness and varied patient demographics. Moreover, there is a heightened emphasis on rare diseases and orphan drugs, backed by regulatory incentives that encourage their development. The advent of digital health technologies, including telemedicine and wearable devices, is improving trial efficiency and enhancing patient engagement. For instance, in November 2023, AstraZeneca PLC introduced a new initiative called Evinova, aimed at enhancing clinical trials through digital solutions that boost efficiency and cut costs. This development is supported by ongoing technological advancements and evolving regulatory conditions.

Rising Investments in R&D to Boost Market Growth

The global clinical trials market is growing rapidly, driven by increased R&D investments across pharmaceuticals, medical devices, biotechnology, and healthcare IT. Companies such as ICON plc, Biogen Inc., Novartis AG, and F. Hoffmann-La Roche AG are at the forefront, advancing innovation and expanding clinical research capabilities. Their contributions highlight the sector's dynamic evolution and expansion. In addition, the inclusion of health technologies such as telemedicine and wearable devices is accelerating the trial process and enhancing patient engagement. For instance, Accenture PLC's strategic investment in QuantHealth Ltd., a company that uses AI to simulate clinical trials in the cloud, demonstrates how R&D funding speeds up the development of treatments, making the process quicker and more cost-effective. These initiatives highlight the significant influence of rising R&D investment on the progress of the clinical trials market.

Increasing Demand for Advanced Treatments Drives Market Growth

Rising demand for novel treatment is a major factor propelling the growth of the clinical trials market. With patients and healthcare professionals demanding better approaches to care, pharmaceutical and biotech organizations are funding significant amounts towards the clinical research world to meet these demands. And that is driving an acceleration of the start-up phase for new clinical trials and exploration of newer drug compounds. For instance, in February 2024, IOVANCE Biotherapeutics, Inc. has received the United States FDA's approval for Amtagvi, a novel cancer therapy - tumor-infiltrating lymphocytes (TIL) therapy. Amtagvi is designed for metastatic melanoma patients who are not eligible for other treatment options. The treatment works by enhancing immune cells within tumors to improve their cancer-fighting capabilities. This development showcases how the pursuit of cutting-edge treatments drives the growth of the clinical trials market, encouraging the creation of innovative therapies and specialized trial services.

Dominance of Phase II Clinical Trial

Phase II clinical trials play a vital role in the growth of the global clinical trials market by evaluating the effectiveness of new treatments on a broader scale. The complexity of these trials drives the demand for advanced services and technologies, increasing the need for specialized management and data analysis. When successful, these trials can lead to faster regulatory approvals and attract additional investment. The larger patient populations involved enhance recruitment and engagement efforts. For instance, as per ClinicalTrials.gov, there are around 94,000 active clinical trials in the field of cancer, of which around 30,000 trials are in Phase II, accounting for 31% of the total ongoing trials as of August 2024.

North America Dominates the Global Clinical Trials Market

North America leads the clinical trials market due to its effective regulatory framework, substantial financial resources, cutting-edge research infrastructure, diverse patient populations, operational excellence, political and economic stability, and a strong focus on innovation and collaboration. These factors collectively establish an optimal environment for conducting high-quality clinical trials, reinforcing North America's pivotal role in advancing global medical research and development. There has been a significant change in the distribution of clinical trials by region. Over the past five years, there was a steady rise in the number of newly recruiting trials' registration in the North America region. According to the WHO data, as of 2022, 168,520 clinical trials were registered in the United States; while 34,041 clinical trials were conducted in Canada.

Future Market Scenario (2024-2031F)

The clinical trials market is poised for impressive gains with the burgeoning trend of personalized medicine which encompasses treatments that are developed specifically for patients based on their genetic profiles and biomarkers. This strategy supports new types of clinical trials, such as adaptive and basket trials, which save costs by being more efficient. Aligning trials with the needs of patients also supports patient recruitment and retention, improving data quality to produce better outcomes. The use of advanced technologies and genomic data will further streamline trials, while supportive regulatory frameworks will speed up approvals. For instance, GSK plc's collaboration with Tempus exemplifies this trend, as GSK utilizes Tempus' AI-driven platform and patient data to enhance trial design, accelerate enrolment, and identify drug targets, boosting R&D success and expediting personalized treatment delivery.

Key Players Landscape and Outlook

Thermo Fisher Scientific Inc., Charles River Laboratories International, Inc., IQVIA, Inc., Laboratory Corporation of America Holdings, Caidya, ICON plc, Medpace Holdings, Inc., Parexel International Corporation, SGS Societe Generale de Surveillance SA, and Fortrea Inc., among others, are some of the leading companies in the clinical trials market, generating the highest revenue from drugs sales recently. The global clinical trials market is competitive, with a huge number of players operating in the local markets as well. Regulatory approvals of company products, mergers and acquisitions, and collaborations are the most common market strategies that have been observed in recent times.

In February 2024, Medidata, a Dassault Systemes company specializing in clinical trial solutions, renewed its partnership with the PPD clinical research business of Thermo Fisher Scientific Inc. The renewed agreement includes the Medidata Platform, Medidata Adjudicate, and additional Medidata Rave products. This collaboration aims to enhance the PPD clinical research business's capabilities in supporting its clients' drug development programs, further advancing clinical trial processes and efficiency.

In September 2023, the US Biomedical Advanced Research and Development Authority (BARDA) partnered with Ireland-based ICON plc to advance COVID-19 vaccine trials under the "Project NextGen" initiative. This project, part of BARDA's Strategic Preparedness and Response division, aims to develop vaccines and therapies for current and future COVID-19 strains. The initiative reflects BARDA's commitment to public-private partnerships, with over USD 5 billion allocated to bolster pandemic preparedness and response.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Clinical Trials Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Phase
    • 4.2.1.1. Phase I
    • 4.2.1.2. Phase II
    • 4.2.1.3. Phase III
    • 4.2.1.4. Phase IV
  • 4.2.2. By Service Type
    • 4.2.2.1. Laboratory Services
    • 4.2.2.2. Bioanalytical and Analytical Testing Services
    • 4.2.2.3. Patient Recruitment and Site Identification
    • 4.2.2.4. Clinical Trial Data Management Services
    • 4.2.2.5. Protocol Designing
    • 4.2.2.6. Medical Device Testing Services
    • 4.2.2.7. Other Services
  • 4.2.3. By Therapeutic Area
    • 4.2.3.1. Oncology
    • 4.2.3.2. Cardiology
    • 4.2.3.3. Neurology
    • 4.2.3.4. Infectious Diseases
    • 4.2.3.5. Other Therapeutic Areas
  • 4.2.4. By Application
    • 4.2.4.1. Small Molecules
    • 4.2.4.2. Vaccines
    • 4.2.4.3. Cell & Gene Therapies
    • 4.2.4.4. Monoclonal Antibodies
    • 4.2.4.5. Other Applications
  • 4.2.5. By Study Design Outlook
    • 4.2.5.1. Interventional
    • 4.2.5.2. Observational
    • 4.2.5.3. Expanded Access
  • 4.2.6. By Sponsor Type
    • 4.2.6.1. Pharmaceutical Companies
    • 4.2.6.2. Medical Device Companies
    • 4.2.6.3. Academic Institutes
  • 4.2.7. By Region
    • 4.2.7.1. North America
    • 4.2.7.2. Europe
    • 4.2.7.3. Asia-Pacific
    • 4.2.7.4. South America
    • 4.2.7.5. Middle East and Africa
  • 4.2.8. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Phase
  • 4.3.2. By Service Type
  • 4.3.3. By Therapeutic Area
  • 4.3.4. By Application
  • 4.3.5. By Study Design Outlook
  • 4.3.6. By Sponsor Type
  • 4.3.7. By Region

5. North America Clinical Trials Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Phase
    • 5.2.1.1. Phase I
    • 5.2.1.2. Phase II
    • 5.2.1.3. Phase III
    • 5.2.1.4. Phase IV
  • 5.2.2. By Service Type
    • 5.2.2.1. Laboratory Services
    • 5.2.2.2. Bioanalytical and Analytical Testing Services
    • 5.2.2.3. Patient Recruitment and Site Identification
    • 5.2.2.4. Clinical Trial Data Management Services
    • 5.2.2.5. Protocol Designing
    • 5.2.2.6. Medical Device Testing Services
    • 5.2.2.7. Other Services
  • 5.2.3. By Therapeutic Area
    • 5.2.3.1. Oncology
    • 5.2.3.2. Cardiology
    • 5.2.3.3. Neurology
    • 5.2.3.4. Infectious Diseases
    • 5.2.3.5. Other Therapeutic Areas
  • 5.2.4. By Application
    • 5.2.4.1. Small Molecules
    • 5.2.4.2. Vaccines
    • 5.2.4.3. Cell & Gene Therapies
    • 5.2.4.4. Monoclonal Antibodies
    • 5.2.4.5. Other Applications
  • 5.2.5. By Study Design Outlook
    • 5.2.5.1. Interventional
    • 5.2.5.2. Observational
    • 5.2.5.3. Expanded Access
  • 5.2.6. By Sponsor Type
    • 5.2.6.1. Pharmaceutical Companies
    • 5.2.6.2. Medical Device Companies
    • 5.2.6.3. Academic Institutes
  • 5.2.7. By Country Share
    • 5.2.7.1. United States
    • 5.2.7.2. Canada
    • 5.2.7.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Clinical Trials Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Phase
        • 5.3.1.2.1.1. Phase I
        • 5.3.1.2.1.2. Phase II
        • 5.3.1.2.1.3. Phase III
        • 5.3.1.2.1.4. Phase IV
      • 5.3.1.2.2. By Service Type
        • 5.3.1.2.2.1. Laboratory Services
        • 5.3.1.2.2.2. Bioanalytical and Analytical Testing Services
        • 5.3.1.2.2.3. Patient Recruitment and Site Identification
        • 5.3.1.2.2.4. Clinical Trial Data Management Services
        • 5.3.1.2.2.5. Protocol Designing
        • 5.3.1.2.2.6. Medical Device Testing Services
        • 5.3.1.2.2.7. Other Services
      • 5.3.1.2.3. By Therapeutic Area
        • 5.3.1.2.3.1. Oncology
        • 5.3.1.2.3.2. Cardiology
        • 5.3.1.2.3.3. Neurology
        • 5.3.1.2.3.4. Infectious Diseases
        • 5.3.1.2.3.5. Other Therapeutic Areas
      • 5.3.1.2.4. By Application
        • 5.3.1.2.4.1. Small Molecules
        • 5.3.1.2.4.2. Vaccines
        • 5.3.1.2.4.3. Cell & Gene Therapies
        • 5.3.1.2.4.4. Monoclonal Antibodies
        • 5.3.1.2.4.5. Other Applications
      • 5.3.1.2.5. By Study Design Outlook
        • 5.3.1.2.5.1. Interventional
        • 5.3.1.2.5.2. Observational
        • 5.3.1.2.5.3. Expanded Access
      • 5.3.1.2.6. By Sponsor Type
        • 5.3.1.2.6.1. Pharmaceutical Companies
        • 5.3.1.2.6.2. Medical Device Companies
        • 5.3.1.2.6.3. Academic Institutes
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Clinical Trials Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Clinical Trials Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Clinical Trials Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Clinical Trials Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Porter's Five Forces Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Clinical Trials

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 15.3.2. Novo Nordisk A/S
  • 15.3.3. IQVIA, Inc.
  • 15.3.4. Laboratory Corporation of America Holdings
  • 15.3.5. Caidya
  • 15.3.6. ICON plc
  • 15.3.7. Medpace Holdings, Inc.
  • 15.3.8. Parexel International Corporation
  • 15.3.9. Charles River Laboratories International, Inc.
  • 15.3.10. SGS Societe Generale de Surveillance SA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer

관련자료